Our final draft guidance published today recommends marstacimab (also called Hympavzi and made by Pfizer) for treating the severe form of blood disorder haemophilia B in people 12 years and over.
We are consulting on draft guidance for cerliponase alfa for treating neuronal ceroid lipofuscinosis type 2 (CLN2), a type of Batten disease.
Final guidance recommends one digital therapy to help children and young people manage their condition.
Today we've recommended a new treatment option for symptoms of endometriosis that can be taken at home.
NICE International has helped Egypt take a crucial step towards a fairer, more efficient healthcare system.
An end of year summary from our chief executive, Dr Sam Roberts.
Our new modular update focuses on how we consider health inequalities when evaluating technologies for use in the NHS, and how you can get involved in suggesting future updates.
Our chief medical officer, Professor Jonathan Benger, explains the crucial role the HST programme plays in encouraging innovation in the treatment of ultra-rare diseases. He also highlights why effective routing is essential to getting the best care to patients across the NHS.
